Sunitinib-Associated Acute Pancreatitis: A Case Report
Sunitinib is a multikinase inhibitor used for the treatment of metastatic renal cell carcinoma. Acute pancreatitis associated with sunitinib is rare. Presently described is a case of a 79-year-old man with metastatic renal cell carcinoma who developed acute pancreatitis following the initiation sunitinib treatment. The development of acute pancreatitis secondary to sunitinib should be considered in patients presenting with abdominal pain after the administration of sunitinib.
1.Ishikawa Y, Aida S, Tamai S, Akasaka Y, Kiguchi H, Akishima-Fukasawa Y, et al. Significance of lymphatic invasion and proliferation on regional lymph node metastasis in renal cell carcinoma. Am J Clin Pathol 2007;128:198–207. [CrossRef]
2. Iacovelli R, Sternberg CN, Porta C, Verzoni E, de Braud F, Escudier B, et al. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr Drug Targets 2015;16:164–70. [CrossRef]
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24. [CrossRef]
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.
5. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1:S41–54.
6. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokineticpharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009;15:7045–52. [CrossRef]
7. Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med 2014;2014:952624. [CrossRef]
8. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:e1–3. [CrossRef]
9. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008;61:515–24. [CrossRef]
10. Ruinemans GM, Balemans C, Mattijssen V, Wiersma-van Tilburg AJ, Smit HJ. Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. Lung Cancer 2010;70:364–5. [CrossRef]
11. Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 2007;100:909–11. [CrossRef]
12. Péron J, Khenifer S, Potier V, Vitry T, Pasquet F, Rassat R, et al. Axitinib-induced acute pancreatitis: a case report. Anticancer Drugs 2014;25:478–9. [CrossRef]
13. Ghatalia P, Morgan CJ, Choueiri TK, Rocha P, Naik G, Sonpavde G. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015;94:136–45. [CrossRef]
14. Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP 2010;11:291–3.
15. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet 2015;386:85–96. [CrossRef]